IL15 and neoplasm: Another approach employed by two groups used an IL-15 receptor fusion construct comprising of an IL-15 superagonist and IL-15 receptor α (IL-15SA/IL-15RA) to increase anti-tumor activity of PB-NK and iPSC-NK cells, respectively, in vitro and in vivo (40, 88).